Does malignant hematopoietic disease result from internal exposure to 239Pu?
Neither Fisher's Exact Test nor linear regression analysis (dose-response relationship) using average skeletal dose from 239Pu as a surrogate for marrow dose could establish a statistically significant association between malignant hematopoietic disease (MHD including leukemia and aleukemia) and exposure to 239Pu among dogs in the Utah beagle colony. In addition, when dog-years at risk was the parameter used to estimate the rate of expected malignant hematopoietic tumors in dogs exposed to 239Pu, the estimate was within the range of the 95% confidence limits of the control dogs for six cases (and also within the 95% confidence limits for five cases when the single case of lymphoma was omitted). It was concluded that if there was an effect of 239Pu exposure on the occurrence of MHD in this beagle experiment, it was not very meaningful. These data could not establish a significant susceptibility to neoplasia of either myeloid or lymphoid tissue of 239Pu exposure.
Lloyd
Ray D
RD
Radiobiology Division Department of Radiology, University of Utah School of Medicine, 2334 CAMT, 729 Arapeen Drive, Salt Lake City, UT 84108-1218, USA. ray.lloyd@hsc.utah.edy
Taylor
Glenn N
GN
Miller
Scott C
SC
D017677:Age Distribution; D000818:Animals; D001822:Body Burden; D004195:Disease Models, Animal; D004285:Dogs; D005260:Female; D019337:Hematologic Neoplasms / Q000453:epidemiology*; D015994:Incidence; D007267:Injections; D007953:Leukemia, Radiation-Induced / Q000453:epidemiology*; D008297:Male; D008954:Models, Biological; D011005:Plutonium / Q000008:administration & dosage* / Q000032:analysis*; D011829:Radiation Dosage; D011874:Radiometry / Q000379:methods*; D012016:Reference Values; D018570:Risk Assessment / Q000379:methods*; D016019:Survival Analysis; D015996:Survival Rate
D011005:Plutonium